10 Best Mid-Cap Healthcare Stocks To Buy Now

5. Vera Therapeutics, Inc. (NASDAQ:VERA)

Hedge Fund Holders: 43 

Vera Therapeutics, Inc (NASDAQ:VERA) is a clinical-stage biotech company developing treatments for serious immunological diseases, including IgAN and lupus nephritis. Atacicept, currently in Phase III trials for immunoglobulin A nephropathy (IgAN) and Phase II trials for lupus nephritis, is a major growth catalyst for Vera. The drug recently received FDA Breakthrough Therapy Designation, which could expedite its market entry. Recent 72-week data from the Phase 2b ORIGIN clinical trial showed consistent and sustained reductions in Gd-IgA1 and hematuria, indicating potential efficacy in treating IgAN

Vera Therapeutics, Inc (NASDAQ:VERA) has significant institutional backing, with 364 institutional owners holding 99.56% of the outstanding shares. As of Q2 2024, 43 hedge fund holders held stakes in the stock with VenBio Select Advisor being the largest stakeholder with 4,309,590 worth $155,920,966. The stock also holds a Strong Buy rating based on 3 Wall Street Analysts. The average price target is $63.00, with a range between $56.00 and $68.00. This target implies a 66.58% increase from the current price of $37.82.

Vera Therapeutics, Inc (NASDAQ:VERA) recently appointed David Johnson as Chief Operating Officer, further strengthening its executive team. This move aligns with the company’s strategy to build a robust leadership structure capable of advancing its pipeline and potential commercialization efforts.